Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). (Q49901672)
Jump to navigation
Jump to search
scientific article published on 15 January 2018
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). |
scientific article published on 15 January 2018 |
Statements
1 reference
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). (English)
1 reference
Eric L Simpson
1 reference
Carsten Flohr
1 reference
Lawrence F Eichenfield
1 reference
Thomas Bieber
1 reference
Howard Sofen
1 reference
Alain Taïeb
1 reference
Ryan Owen
1 reference
Wendy Putnam
1 reference
Marcela Castro
1 reference
Kendra DeBusk
1 reference
Chin-Yu Lin
1 reference
Athina Voulgari
1 reference
Karl Yen
1 reference
Theodore A Omachi
1 reference
15 January 2018
1 reference